CST, 59870SF, APP (Aducanumab Biosimilar) Human Monoclonal Antibody

Monoclonal Antibody for studying APP. Validated for Neutralizing. Highly specific and rigorously validated in-house, APP (Aducanumab Biosimilar) Human Monoclonal Antibody (CST #59870) is ready to ship. Product Usage Information This product is intended for research use only (RUO). Optimal dilutions/concentrations should be determined by the end user. Formulation Supplied in 1X PBS, BSA and Azide Free. Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity APP (Aducanumab Biosimilar) Human Monoclonal Antibody was confirmed to bind to its intended target aggregated Aβ using bio-layer interferometry. Species Reactivity: Human Source / Purification APP (Aducanumab Biosimilar) Human mAb is produced at Cell Signaling Technology. Aducanumab is an antibody directed against aggregated Aβ. Background Amyloid β (Aβ) precursor protein (APP) is a 100-140 kDa transmembrane glycoprotein that exists as several isoforms (1). The amino acid sequence of APP contains the amyloid domain, which can be released by a two-step proteolytic cleavage (1). The extracellular deposition and accumulation of the released Aβ fragments form the main components of amyloid plaques in Alzheimer's disease (1). APP can be phosphorylated at several sites, which may affect the proteolytic processing and secretion of this protein (2-5). Phosphorylation at Thr668 (a position corresponding to the APP695 isoform) by cyclin-dependent kinase is cell-cycle dependent and peaks during G2/M phase (4). APP phosphorylated at Thr668 exists in adult rat brain and correlates with cultured neuronal differentiation (5,6). Alternate Names A4; AAA; ABETA; Abeta40; Abeta42; ABPP; AD1; AICD-50; AICD-57; AICD-59; AID(50); AID(57); AID(59); Alpha-CTF; Alpha-secretase C-terminal fragment; Alzheimer disease amyloid protein; Amyloid beta; amyloid beta (A4) precursor protein; Amyloid beta A4 protein; amyloid beta precursor protein; Amyloid intracellular domain 50; Amyloid intracellular domain 57; Amyloid intracellular domain 59; Amyloid precursor protein; Amyloid-beta A4 protein; Amyloid-beta precursor protein; Amyloid-beta protein 40; Amyloid-beta protein 42; APP; APPI; Beta Amyloid; beta-amyloid peptide; beta-amyloid peptide(1-40); beta-amyloid peptide(1-42); beta-amyloid precursor protein; Beta-amyloid protein 40; Beta-amyloid protein 42; Beta-APP40; Beta-APP42; Beta-CTF; Beta-secretase C-terminal fragment; C31; C80; C83; C99; Cerebral vascular amyloid peptide; CTFgamma; CVAP; Gamma-CTF(50); Gamma-CTF(57); Gamma-CTF(59); Gamma-secretase C-terminal fragment 50; Gamma-secretase C-terminal fragment 57; Gamma-secretase C-terminal fragment 59; N-APP; P3(40); P3(42); peptidase nexin-II; PN-II; PN2; PreA4; Protease nexin-II; S-APP-alpha; S-APP-beta; Soluble APP-alpha; Soluble APP-beta; testicular tissue protein Li 2 Specification REACTIVITY: H SENSITIVITY: Endogenous Source/Isotype: Human IgG kappa